Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lowered its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 67.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,321 shares of the company's stock after selling 68,995 shares during the period. Russell Investments Group Ltd. owned approximately 0.08% of Keros Therapeutics worth $527,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Wells Fargo & Company MN grew its position in shares of Keros Therapeutics by 37.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,208 shares of the company's stock valued at $241,000 after purchasing an additional 4,153 shares in the last quarter. Bryce Point Capital LLC bought a new stake in shares of Keros Therapeutics in the 4th quarter valued at about $445,000. Geode Capital Management LLC raised its position in Keros Therapeutics by 5.5% during the 4th quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after purchasing an additional 39,815 shares during the last quarter. Clearbridge Investments LLC bought a new position in Keros Therapeutics during the 4th quarter valued at approximately $3,009,000. Finally, Norges Bank purchased a new stake in Keros Therapeutics in the fourth quarter worth $1,027,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Price Performance

KROS traded down $0.20 during trading hours on Tuesday, reaching $14.06. The company's stock had a trading volume of 92,528 shares, compared to its average volume of 798,694. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a market cap of $570.99 million, a PE ratio of -2.71 and a beta of 1.39. The business's 50-day moving average is $11.63 and its 200-day moving average is $27.13.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. Analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Piper Sandler decreased their target price on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research report on Friday, January 17th. Truist Financial dropped their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Wedbush reiterated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Finally, Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $40.33.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the firm's stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 22.90% of the stock is currently owned by insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.